Sueldos y Compensación en Stoke Therapeutics

Stoke Therapeutics develops antisense oligonucleotide medicines to treat severe genetic diseases using its proprietary technology. Its lead candidate, STK-001, is in clinical trials for Dravet syndrome, while STK-002 is in preclinical development for autosomal dominant optic atrophy. The company has a collaboration agreement with Acadia Pharmaceuticals for RNA-based medicines for rare genetic neurodevelopmental diseases. Stoke Therapeutics was founded in 2014 and is based in Bedford, Massachusetts.